Search
AMGN-0007
go.drugbank.com/drugs/DB06511ExperimentalRecombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
MP4
go.drugbank.com/drugs/DB05313InvestigationalMP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalHMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. … IPL 576,092 has previously been investigated as a treatment for asthma.
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
RG2417
go.drugbank.com/drugs/DB05055InvestigationalRG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential … The rationale for uridine therapy in neuropsychiatric disorders is supported by preclinical and clinical research.
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
Synonyms: BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL-, N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDEPGX-100
go.drugbank.com/drugs/DB06114InvestigationalIt is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity. … PGX-100 is an intravenous dosage form of modified heparin.
AM103
go.drugbank.com/drugs/DB05225ExperimentalAM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation … It is being developed by Amira.
Amediplase
go.drugbank.com/drugs/DB06679ExperimentalAmediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.
Pramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. … It was also previously approved in the United States with orphan drug designation [L1469].